Evidence map›Paper›PMID 32594382›Full record

ArticleCellular and molecular neurobiology2021

Mesenchymal Stem Cells Ameliorate Cuprizone-Induced Demyelination by Targeting Oxidative Stress and Mitochondrial Dysfunction.

Elham Shiri, Parichehr Pasbakhsh, Maryam Borhani-Haghighi, Zohreh Alizadeh, Saied Nekoonam, Sina Mojaverrostami, Vahid Pirhajati Mahabadi, Ali Mehdi, Kazem Zibara, Iraj Ragerdi Kashani

Open access · greenAbstract read
In one paragraph

Article in Cellular and molecular neurobiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 1 pooled it
3.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 1 synthesis or guideline pooled it, 45 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Overexpression ofCurrent issues in molecular biology · 2023
    Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Elham ShiriDepartment of Anatomy, Tehran University of Medical Sciences, Tehran, Iran.
Parichehr PasbakhshDepartment of Anatomy, Tehran University of Medical Sciences, Tehran, Iran.
Maryam Borhani-HaghighiDepartment of Anatomy, Tehran University of Medical Sciences, Tehran, Iran.
Zohreh AlizadehEndometrium and Endometriosis Research Center, Hamadan University of Medical Sciences, Hamadan, Iran.
Saied NekoonamDepartment of Anatomy, Tehran University of Medical Sciences, Tehran, Iran.
Sina MojaverrostamiDepartment of Anatomy, Tehran University of Medical Sciences, Tehran, Iran.
Vahid Pirhajati MahabadiNeuroscience Research Center, Vice-Chancellor for Research and Technology, Iran University of Medical Sciences, Tehran, Iran.
Ali MehdiPRASE and Faculty of Agriculture, Lebanese University, Beirut, Lebanon.
Kazem ZibaraER045, PRASE and Biology Department, Faculty of Sciences-I, Lebanese University, Beirut, Lebanon. kzibara@ul.edu.lb.ORCID http://orcid.org/0000-0002-9887-072X
Iraj Ragerdi KashaniDepartment of Anatomy, Tehran University of Medical Sciences, Tehran, Iran. ragerdi@tums.ac.ir.
Tehran University of Medical Sciences · IRLebanese University · LBHamedan University of Medical Sciences · IRIran University of Medical Sciences · IR

Funding

Tehran University of Medical Sciences and Health Services 97-03-30-39671Université Libanaise 2017-25652
6 · The paper itself

Abstract

Multiple sclerosis (MS) is an inflammatory demyelinating disease of the central nervous system. The main causes of MS disease progression, demyelination, and tissue damage are oxidative stress and mitochondrial dysfunction. Hence, the latter are considered as important therapeutic targets. Recent studies have demonstrated that mesenchymal stem cells (MSCs) possess antioxidative properties and are able to target mitochondrial dysfunction. Therefore, we investigated the effect of transplanting Wharton's jelly-derived MSCs in a demyelination mouse model of MS in which mice were fed cuprizone (CPZ) for 12 weeks. CPZ is a copper chelator that impairs the activity of cytochrome oxidase, decreases oxidative phosphorylation, and produces degenerative changes in oligodendrocytes, leading to toxic demyelination similar to those found in MS patients. Results showed that MSCs caused a significant increase in the percentage of myelinated areas and in the number of myelinated fibers in the corpus callosum of the CPZ + MSC group, compared to the CPZ group, as assessed by Luxol fast blue staining and transmission electron microscopy. In addition, transplantation of MSCs significantly increased the number of oligodendrocytes while decreasing astrogliosis and microgliosis in the corpus callosum of the CPZ + MSC group, evaluated by immunofluorescence. Moreover, the mechanism by which MSCs exert these physiological effects was found to be through abolishing the effect of CPZ on oxidative stress markers and mitochondrial dysfunction. Indeed, malondialdehyde significantly decreased while glutathione and superoxide dismutase significantly increased in CPZ + MSC mice group, in comparison witth the CPZ group alone. Furthermore, cell therapy with MSC transplantation increased the expression levels of mitochondrial biogenesis transcripts PGC1α, NRF1, MFN2, and TFAM. In summary, these results demonstrate that MSCs may attenuate MS by promoting an antioxidant response, reducing oxidative stress, and improving mitochondrial homeostasis.

Indexed as

AnimalsCuprizoneDemyelinating DiseasesDisease Models, AnimalHumansMaleMesenchymal Stem CellsMiceMice, Inbred C57BLMitochondriaMultiple SclerosisMyelin SheathOligodendrogliaOxidative StressRemyelinationCuprizoneCuprizoneMesenchymal stem cellsMitochondriaMultiple sclerosisMyelinationOxidative stress

Identifiers

PMID32594382
PMCPMC11448649
OpenAlexW3037534488

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.